Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $10.6 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas.
Shares of this specialty chemicals giant have underperformed the broader market over the past year. RVTY has gained 6.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 27.4%. In 2026, RVTY’s stock fell 1.4%, compared to the SPX’s 8.8% rise on a YTD basis.